US equities |
NVDA $239.81 ▲+2.50% SPCX $169.57 ▲+6.67% MU $1,060.59 ▼-1.33% TSLA $380.86 ▲+2.77% SNDK $1,692.73 ▼-1.58% MSFT $528.52 ▲+2.12% INTC $116.44 ▼-2.42% META $743.62 ▲+2.13%
FinancialContent

Articles published by Sesen Bio

News headline image
Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Provides Strategic Update
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Further Enhances Team with Key Hires
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Strengthens Medical Team
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Productive CMC Type A Meeting with the FDA
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Expands CMC and Clinical Teams
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces New Appointments to its Board of Directors
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Strengthens Senior Leadership Team
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sesen Bio
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend “FOR” Proposal to Increase Authorized Shares
From Sesen Bio
Via Business Wire
Tickers SESN